Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs Wix.Com Ltd (WIX) Price & Performance

ResMed Inc.Trade
Wix.Com LtdTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs Wix.Com Ltd — how do they compare? ResMed Inc. trades at $225.1 (market cap $32.61B), while Wix.Com Ltd trades at $66.95 (market cap $2.79B). The key difference: ResMed Inc. is far larger — about 11.7× Wix.Com Ltd's market cap, and ResMed Inc. pays a 1.17% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.

RMDWIX
Market Cap
$32.61B$2.79B
Sector
HealthTechnology
52-Week High
$293.73$184.24
52-Week Low
$182.82$40.43
Enterprise Value
$31.97B$3.87B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.

The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.

Wix.Com Ltd

WIX trades at $66.60, up 6.69% today, with a bullish technical signal from moving averages and a consensus analyst price target of $79.75. Revenue grew to $1.99B in 2025, though net income margin remains negative at -8.19%. Recent news includes the launch of Symphony by Wix, an AI system for SMBs, but the stock faces multiple class-action lawsuits following a 27% drop after Q1 2026 earnings missed expectations.

The outlook is mixed: strong revenue growth and analyst buy ratings suggest upside, but legal risks and volatile earnings pose significant challenges. Investors should weigh the high P/E of 62.84 against competitive pressures in the website-building space.

Returns comparison

Trailing returns across standard periods

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD

About Wix.Com Ltd

Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.

Read more on WIX